Why Alector, Inc.’s (ALEC) Stock Is Up 7.57%
As of Thursday, July 30, Alector, Inc.’s ALEC share price has surged by 7.57%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer’s disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson’s disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer’s disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson’s disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Alector, Inc.’s (ALEC) Stock Is Up 5.59%
As of Tuesday, July 21, Alector, Inc.’s ALEC share price has surged by 5.59%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Alector, Inc.’s (ALEC) Stock Is Down 5.33%
As of Thursday, July 16, Alector, Inc.’s ALEC share price has dipped by 5.33%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Alector, Inc.’s (ALEC) Stock Is Up 6.12%
As of Wednesday, July 15, Alector, Inc.’s ALEC share price has surged by 6.12%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Alector, Inc.’s (ALEC) Stock Is Down 8.56%
As of Friday, July 10, Alector, Inc.’s ALEC share price has dipped by 8.56%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $179.9 | $251.9 | 27% |
|
| Shares Out (Mil) | 110.6 | 50.8 | 64% |
|
| Institutional Ownership | 92.1% | 92.0% | 61% |
|
| Float (Mil) | 93.8 | 40.5 | 60% |
|
| Beta | 0.65 | 0.95 | 38% |
|
| Avg Daily Volume (000s) | 406 | 447 | 56% |
|
| Price Change (52-week) |
0.6% | 54.2% | 46% |
|
| Growth | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.1%) | 14.0% | 17% |
|
| Net Income (5yr) | 5.6% | (9.8%) | 48% |
|
| EPS (5yr) | 10.7% | 16.3% | 47 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 21.3% | (15.6%) | 80% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 7 | |
| Current EPS | ($0.228) | ($0.883) | ($0.700) | |
| Month Ago EPS | ($0.228) | ($0.883) | ($0.700) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.200) | ($0.884) | ($0.889) | |
| Year/Year Chg | 10.1% | (36.4%) | (48.3%) | |
| Financials | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $18 | $39 | 12% |
|
| Net Income (TTM) (Mil) | ($125) | ($43) | 9% |
|
| EPS (TTM) | ($1.185) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($173) | ($30) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $39 | $3 | 69% |
|
| Long-Term Debt (Q1) (Mil) | $24 | $5 | 34% |
|
| Enterprise Value (Q1) (Mil) | $61 | $182 | 17% |
|
| Valuation | ALEC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 18.00 | 2.60 | 95% |
|
| P/E | na | 18.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ALEC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (482.5%) | 63.8% | 0% |
|
| Net Margin | (680.8%) | (64.7%) | 1% |
|
| ROA | (38.7%) | (49.7%) | 14% |
|
| ROE | (238.9%) | (55.4%) | 4% |
|
| Liabilities to Assets | 95.7% | 30.3% | 92% |
|
| F-Score | 1 | 3 | 1% |
|
Alector, Inc. did not pass any screens on 7/30/2026.
